Premium
Altered levels of insulin‐like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction
Author(s) -
Christians Julian K.,
Gruslin Andrée
Publication year - 2010
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.2583
Subject(s) - proteases , intrauterine growth restriction , placenta , preeclampsia , endocrinology , insulin like growth factor binding protein , medicine , growth factor , insulin like growth factor , proteolysis , placental growth factor , pregnancy , downregulation and upregulation , biology , insulin , fetus , receptor , enzyme , gene , biochemistry , genetics
Abstract Intrauterine growth restriction (IUGR) and preeclampsia (PE) are leading causes of perinatal and maternal morbidity and mortality. Many studies have found association between low levels of insulin‐like growth factor binding protein (IGFBP) proteases in the first trimester maternal circulation and the risk of subsequent development of PE and/or IUGR. These results are generally interpreted to reflect decreased production of the proteases by the placenta, leading to reduced proteolysis of IGFBPs and lower free levels of insulin‐like growth factor (IGF), resulting in diminished feto‐placental development. However, the association between low circulating levels of placental proteins early in pregnancy and the subsequent development of IUGR and/or PE could be due to low exchange in the placenta and not due to reduced production. In contrast, late in pregnancy, the circulating levels of these proteins and their expression in the placenta are often elevated in PE, which may reflect upregulation to compensate for abnormal placental development, that is an adaptive mechanism to increase IGFBP proteolysis, increase local IGF levels and promote feto‐placental growth. Further research into the biological mechanisms underlying these associations will aid the identification of high‐risk pregnancies and the development of therapeutic targets for diseases for which there are presently no preventative measures. Copyright © 2010 John Wiley & Sons, Ltd.